Cryolife Inc (NYSE:CRY) VP Jean F. Holloway sold 8,654 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $32.00, for a total value of $276,928.00. Following the completion of the sale, the vice president now directly owns 67,020 shares in the company, valued at approximately $2,144,640. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of CRY stock traded up $0.42 during mid-day trading on Thursday, hitting $28.54. The company’s stock had a trading volume of 101,700 shares, compared to its average volume of 196,516. Cryolife Inc has a 52-week low of $23.99 and a 52-week high of $36.05. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69. The stock has a market capitalization of $1.06 billion, a P/E ratio of 109.77 and a beta of 0.54.
Cryolife (NYSE:CRY) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.04. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The firm had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $66.37 million. During the same quarter in the previous year, the business earned $0.02 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. As a group, analysts anticipate that Cryolife Inc will post 0.31 earnings per share for the current year.
A number of brokerages have commented on CRY. TheStreet cut Cryolife from a “b-” rating to a “c+” rating in a research note on Wednesday, May 22nd. ValuEngine cut Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 15th. Zacks Investment Research lowered Cryolife from a “buy” rating to a “hold” rating in a research report on Thursday, January 31st. Needham & Company LLC reiterated a “hold” rating on shares of Cryolife in a research report on Sunday, May 12th. Finally, Canaccord Genuity restated a “buy” rating and set a $35.00 price target (up from $32.00) on shares of Cryolife in a research report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Cryolife currently has an average rating of “Buy” and a consensus price target of $31.91.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Cryolife Inc (CRY) VP Sells 8,654 Shares of Stock” was published by Rockland Register and is owned by of Rockland Register. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://rocklandregister.com/2019/05/30/cryolife-inc-cry-vp-jean-f-holloway-sells-8654-shares-of-stock.html.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.